Jpmorgan Chase & CO Enanta Pharmaceuticals Inc Transaction History

Jpmorgan Chase & CO

  • $1.27 Trillion
  • Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 134,202 shares of ENTA stock, worth $1.54 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
134,202
Previous 163,113 17.72%
Holding current value
$1.54 Million
Previous $937,000 21.02%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
SELL
$4.82 - $8.49 $139,351 - $245,454
-28,911 Reduced 17.72%
134,202 $740,000
Q4 2024

Feb 12, 2025
SELL
$5.75 - $12.99 $462,961 - $1.05 Million
-80,515 Reduced 33.05%
163,113 $937,000
Q3 2024

Dec 26, 2024
BUY
$10.05 - $16.54 $855,074 - $1.41 Million
85,082 Added 53.66%
243,628 $2.53 Million
Q3 2024

Nov 08, 2024
BUY
$10.05 - $16.54 $855,074 - $1.41 Million
85,082 Added 53.66%
243,628 $2.53 Million
Q2 2024

Dec 26, 2024
SELL
$11.43 - $17.02 $972,487 - $1.45 Million
-85,082 Reduced 34.92%
158,546 $2.06 Million
Q2 2024

Aug 12, 2024
BUY
$11.43 - $17.02 $234,303 - $348,892
20,499 Added 14.85%
158,546 $2.06 Million
Q1 2024

Dec 26, 2024
SELL
$10.08 - $17.46 $1.06 Million - $1.84 Million
-105,581 Reduced 43.34%
138,047 $2.41 Million
Q1 2024

May 10, 2024
SELL
$10.08 - $17.46 $128,761 - $223,034
-12,774 Reduced 8.47%
138,047 $2.41 Million
Q4 2023

Dec 26, 2024
SELL
$8.18 - $10.78 $759,161 - $1 Million
-92,807 Reduced 38.09%
150,821 $1.42 Million
Q4 2023

Feb 12, 2024
SELL
$8.18 - $10.78 $378,840 - $499,254
-46,313 Reduced 23.49%
150,821 $1.42 Million
Q3 2023

Nov 14, 2023
BUY
$11.09 - $22.13 $157,211 - $313,714
14,176 Added 7.75%
197,134 $2.2 Million
Q2 2023

Aug 11, 2023
BUY
$20.68 - $39.85 $326,309 - $628,793
15,779 Added 9.44%
182,958 $3.92 Million
Q1 2023

May 18, 2023
BUY
$38.82 - $54.59 $965,763 - $1.36 Million
24,878 Added 17.48%
167,179 $6.76 Million
Q1 2023

May 11, 2023
SELL
$38.82 - $54.59 $1.52 Million - $2.14 Million
-39,238 Reduced 21.61%
142,301 $5.75 Million
Q4 2022

Feb 13, 2023
BUY
$40.77 - $53.73 $363,505 - $479,056
8,916 Added 5.17%
181,539 $8.45 Million
Q3 2022

Nov 14, 2022
SELL
$48.29 - $71.27 $242,946 - $358,559
-5,031 Reduced 2.83%
172,623 $8.95 Million
Q2 2022

Aug 11, 2022
BUY
$38.13 - $76.93 $5.27 Million - $10.6 Million
138,097 Added 349.11%
177,654 $8.4 Million
Q1 2022

May 11, 2022
BUY
$56.06 - $74.11 $129,050 - $170,601
2,302 Added 6.18%
39,557 $2.82 Million
Q4 2021

Feb 10, 2022
SELL
$60.19 - $97.37 $22,631 - $36,611
-376 Reduced 1.0%
37,255 $2.79 Million
Q3 2021

Nov 12, 2021
BUY
$41.02 - $58.65 $1.54 Million - $2.21 Million
37,631 New
37,631 $2.14 Million

Others Institutions Holding ENTA

# of Institutions
107
Shares Held
18.7M
Call Options Held
50K
Put Options Held
0
View Full List

About ENANTA PHARMACEUTICALS INC

ENTA Quotes by TradingView
  • Ticker ENTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,724,900
  • Market Cap $238M
  • Description
  • Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...
More about ENTA
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email